BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nelmastobart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nelmastobart\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07306624-2637@assetmemo.bio
DTSTAMP:20261121T010146Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nelmastobart: Phase 2 readout est. (NCT07306624)
DESCRIPTION:Nelmastobart\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 lmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer\nEs
 timated primary completion: 31 August 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nelmastobart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07306624
URL:https://assetmemo.bio/drug/nelmastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07656038-2637@assetmemo.bio
DTSTAMP:20261121T010146Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Nelmastobart: Phase 1 readout est. (NCT07656038)
DESCRIPTION:Nelmastobart\, phase 1.\nStudy: Nelmastobart in Combination Wit
 h Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer\nEstim
 ated primary completion: 31 July 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nelmastobart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07656038
URL:https://assetmemo.bio/drug/nelmastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
